Biolase Technology (BIOL) 2.21 $BIOL
BIOLASE Announces That Non-Executive Board Member Federico Pignatelli Has Withdrawn His Lawsuit against Company
Business Wire - Wed Jul 30, 5:34PM CDT
BIOLASE, Inc. (BIOL), the world's leading dental laser manufacturer and distributor, announced today that non-executive board member Federico Pignatelli yesterday withdrew his lawsuit against the Company and four other members of BIOLASE's board of directors.
BIOLASE Sends Letter to Stockholders
Business Wire - Wed Jul 30, 8:01AM CDT
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading dental laser manufacturer and distributor, today sent a letter to its stockholders.
BIOLASE to Raise $12 Million from Institutional and Individual Investors in Private Placement
Business Wire - Mon Jul 21, 8:05AM CDT
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading dental laser manufacturer and distributor, announced today that Jack W. Schuler, Oracle Partners, L.P. and other Oracle funds, Birchview Capital and certain BIOLASE directors and officers have agreed to purchase $12 million of unregistered shares of BIOLASE common stock in a private placement transaction. Under the terms of the private placement, BIOLASE has agreed to sell an aggregate of 6,250,000 shares of its common stock at the price of $1.92 per share. In connection with the transaction, BIOLASE agreed to use commercially reasonable efforts to file within 30 days of the closing a registration statement with the Securities and Exchange Commission to register the resale of the shares issued at the closing.
BIOLASE Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Business Wire - Mon Jul 14, 8:36PM CDT
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading manufacturer and distributor of dental lasers, today announced that on July 13, 2014, Jeffrey M. Nugent, the Company's Acting Chief Executive Officer, received options to purchase 172,282 shares of the Company's common stock with an exercise price of $1.98 per share, the closing price per share on July 10, 2014. In addition, Mr. Nugent received an award of restricted stock units ("RSUs"
with respect to 37,879 shares of the Company's common stock. One-sixth of the stock options and the RSUs vest immediately, with the remaining five-sixths vesting ratably on a monthly basis over a twelve-month period ending on July 13, 2015, subject to Mr. Nugent's continued service with the Company through the applicable vesting dates.
BIOLASE SHAREHOLDER ALERT - Andrews & Springer LLC is Investigating Biolase, Inc. for Possible Violations of Securities Laws and Breaches of Fiduciary Duty
GlobeNewswire - Mon Jul 07, 7:30AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating the Board of Directors of Biolase, Inc. ("Biolase" or the "Company" for possible corporate misconduct and violations of securities laws as recently announced in the former CEO's letter to the Company's board of directors.
Biolase Director Federico Pignatelli Initiates Process to Obtain Books and Records to Investigate Suspected Wrongdoing, Mismanagement and Corporate Governance Failures
Business Wire - Fri Jun 27, 4:20PM CDT
Federico Pignatelli, former CEO and current director and stockholder of Biolase, Inc. (Nasdaq:BIOL), has initiated a process pursuant to Section 220(b) and (d) of the Delaware General Corporation Law to obtain certain books and records from Biolase management relating to suspected wrongdoing, mismanagement and corporate governance failures by the company's board of directors.
BIOLASE Announces Annual Meeting Date and Record Date
Business Wire - Thu Jun 26, 10:50PM CDT
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading manufacturer and distributor of dental lasers, is pleased to announce that its 2014 Annual Meeting of Shareholders will be held on August 27, 2014, at 11:00 a.m. Pacific Time at the Company's corporate headquarters, located at 4 Cromwell, Irvine, California, 92618. The Board of Directors has established July 22, 2014 as the record date for determining the stockholders entitled to vote at the 2014 Annual Shareholders Meeting.
BIOLASE Announces Significant Leadership Changes
Marketwire - Wed Jun 18, 1:27AM CDT
BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, today announced a series of moves with the intention of strengthening the Company's leadership, worldwide competitiveness and the focus on its professional customers and their patients.
Why Biolase (BIOL) Stock Is Higher Today
at The Street - Tue Jun 17, 10:09AM CDT
Biolase (BIO) stock is higher today after CEO Federico Pignatelli resigned following a Delaware Supreme Court's ruling last week over false advertising.
Oracle Partners Decisively Wins Shareholder Litigation Against Biolase, Inc.
Business Wire - Fri Jun 13, 9:28AM CDT
--Paul Clark Confirmed as Biolase Independent Director
BIOLASE Responds to Fotona Press Release Regarding Orange County, CA False Advertising Lawsuit
Marketwire - Thu Jun 12, 12:14PM CDT
BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, including the Company's proprietary WaterLase(R), and a pioneer in laser surgery in other medical specialties, as well as a distributor of digital radiography, intra oral scanners, and chair-side milling machines and 3-D printers for dentistry, today announced that it responds to clarify that this legal action is solely related to a false advertising and defamation suit filed by BIOLASE with the United States District Court in Orange County, California and does not affect the German Patent Infringement Suit won by BIOLASE in May awarding cash damages and injunctive relief. In addition, while the Orange County Court granted Fotona's Motion to Dismiss, they also elected to grant BIOLASE a 14 day Leave to Amend the Dismissed Claims which BIOLASE intends to pursue.
Federal Judge Dismisses Biolase Lawsuit Against Fotona
PR Newswire - Wed Jun 11, 1:00PM CDT
The Fotona companies, (Fotona), announced today, that on June 2, 2014, the federal judge in Orange County, California has dismissed all claims of Biolase's (BIOL) lawsuit against Fotona d.d. and Fotona LLC. Among other things, Biolase had challenged Fotona's statements that its lasers were faster for hard tissue dental applications than Biolase's lasers. The Court concluded that Biolase has failed to state a claim for false advertising since Fotona's advertising statements are accurate restatements of conclusions in scientific journal articles. Fotona will continue to vigorously defend its products, and take action against false or misleading claims.
BIOLASE Launches State-of-the-Art E-Learning Platform for Dentistry
Marketwire - Thu Jun 05, 1:45AM CDT
BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, including the company's proprietary WaterLase(R), and a pioneer in laser surgery in other medical specialties, as well as a distributor of digital radiography devices, intra-oral scanners, and chairside milling machines and 3-D printers for dentistry, today announced the launch of its state-of-the-art e-learning platform: BIOLASE Campus (www.biolasecampus.com). The site will go live on Monday, June 9, 2014.
Oracle Partners Announces a Victory in Shareholder Litigation Against Biolase, Inc.
PR Newswire - Fri May 30, 8:00AM CDT
Oracle Partners, L.P. ("Oracle Partners" , Biolase, Inc.'s ("Biolase" or the "Company" (Nasdaq: BIOL) largest shareholder, announced that it has won a significant victory in its shareholder litigation against Biolase.
UPDATE: BIOLASE Featured in Dental Tribune Report on Italy's Rimini Dental Conference
Marketwire - Thu May 29, 1:18PM CDT
BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, including the Company's proprietary WaterLase(R), and a pioneer in laser surgery in other medical specialties, as well as a distributor of digital radiography, intra oral scanners, and chair-side milling machines and 3-D printers for dentistry, today announced that it had been featured in a report on Dental Tribune's website.
BIOLASE Featured in Dental Tribune Report on Italy's Rimini Dental Conference
Marketwire - Thu May 29, 9:58AM CDT
BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, including the Company's proprietary WaterLase(R), and a pioneer in laser surgery in other medical specialties, as well as a distributor of digital radiography, intra oral scanners, and chair-side milling machines and 3-D printers for dentistry, today announced that it had been featured in a report on Dental Tribune's website.
Company calls BIOLASE Website Representations False and Misleading
Marketwire - Mon Mar 24, 12:53PM CDT
Millennium Dental Technologies Inc. (MDT) -- the world leader in dentist satisfaction of its signature value propositions LANAP(R) and LAPIP(TM) protocols -- has issued comments regarding false and misleading representations made by Biolase Inc. regarding a former MDT management level employee. The company considers the statements made by Biolase regarding MDT former vice president of global sales and marketing, Brian Jaffe, to be false and misleading.
BIOLASE announces formation of four member board
M2 - Mon Mar 24, 5:15AM CDT
Biomedical company BIOLASE (NASDAQ:BIOL) disclosed on Friday that the Chancery Court of Delaware has announced a status quo order to establish a board of directors.
Concise Analysis of the International Dental Diagnostic and Surgical Equipment Market
M2 - Mon Mar 24, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q52vzz/global_dental) has announced the addition of the "Concise Analysis of the International Dental Diagnostic and Surgical Equipment Market" report to their offering. The adoption of 3D cone-beam dental imaging in general dentistry, coupled with innovative implant procedures, oral surgery, temporo-mandibular joint analysis, and periodontal and orthodontic procedures, is an emerging trend that is expected to positively impact the Global Dental Diagnostic and Surgical Equipment market. Such innovative procedures make it possible to look at a tooth from any direction or orientation and in 3D, which eliminates much of the guesswork commonly experienced with 2D radiographs. The technique allows views of critical anatomy such as bone structure and tooth orientation to be captured. It aids in the accurate planning of procedures such as implants and oral surgery for more predictable outcomes, in addition to reducing treatment time and radiation. According to the report, one of the main drivers of this market is the increasing elderly population and the associated dental problems such as root caries, periodontal disease, missing teeth, edentulism, poor quality of alveolar ridges, various types of oral cancers, and caries. An increase in the edentulous population is also increasing demand for dental imaging and surgeries. Further, the report states that the market is experiencing challenges such as a lack of awareness of the risk of oral cancer, especially in developing countries such as Singapore, China, Brazil, and India. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Scope of the Report 4. Market Research Methodology 5. Introduction 6. Market Landscape 7. Market Segmentation by Product 8. Geographical Segmentation 9. Key Leading Countries 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 18. Key Vendor Analysis 19. Other Reports in this Series Companies Mentioned: - 3M Healthcare Ltd. - A-dec Inc. - Aribex Inc. - BIOLASE Inc. - Carestream Health Inc. - Danaher Corp. - Dental Equipment LLC and GC Corp. - Planmeca Oy. - Sirona Dental Systems Inc. For more information visit http://www.researchandmarkets.com/research/q5...bal_dental
BIOLASE Announces That Non-Executive Board Member Federico Pignatelli Has Withdrawn His Lawsuit against Company
Business Wire - Wed Jul 30, 5:34PM CDT
BIOLASE, Inc. (BIOL), the world's leading dental laser manufacturer and distributor, announced today that non-executive board member Federico Pignatelli yesterday withdrew his lawsuit against the Company and four other members of BIOLASE's board of directors.
BIOLASE Sends Letter to Stockholders
Business Wire - Wed Jul 30, 8:01AM CDT
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading dental laser manufacturer and distributor, today sent a letter to its stockholders.
BIOLASE to Raise $12 Million from Institutional and Individual Investors in Private Placement
Business Wire - Mon Jul 21, 8:05AM CDT
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading dental laser manufacturer and distributor, announced today that Jack W. Schuler, Oracle Partners, L.P. and other Oracle funds, Birchview Capital and certain BIOLASE directors and officers have agreed to purchase $12 million of unregistered shares of BIOLASE common stock in a private placement transaction. Under the terms of the private placement, BIOLASE has agreed to sell an aggregate of 6,250,000 shares of its common stock at the price of $1.92 per share. In connection with the transaction, BIOLASE agreed to use commercially reasonable efforts to file within 30 days of the closing a registration statement with the Securities and Exchange Commission to register the resale of the shares issued at the closing.
BIOLASE Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Business Wire - Mon Jul 14, 8:36PM CDT
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading manufacturer and distributor of dental lasers, today announced that on July 13, 2014, Jeffrey M. Nugent, the Company's Acting Chief Executive Officer, received options to purchase 172,282 shares of the Company's common stock with an exercise price of $1.98 per share, the closing price per share on July 10, 2014. In addition, Mr. Nugent received an award of restricted stock units ("RSUs"
with respect to 37,879 shares of the Company's common stock. One-sixth of the stock options and the RSUs vest immediately, with the remaining five-sixths vesting ratably on a monthly basis over a twelve-month period ending on July 13, 2015, subject to Mr. Nugent's continued service with the Company through the applicable vesting dates. BIOLASE SHAREHOLDER ALERT - Andrews & Springer LLC is Investigating Biolase, Inc. for Possible Violations of Securities Laws and Breaches of Fiduciary Duty
GlobeNewswire - Mon Jul 07, 7:30AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating the Board of Directors of Biolase, Inc. ("Biolase" or the "Company"
for possible corporate misconduct and violations of securities laws as recently announced in the former CEO's letter to the Company's board of directors. Biolase Director Federico Pignatelli Initiates Process to Obtain Books and Records to Investigate Suspected Wrongdoing, Mismanagement and Corporate Governance Failures
Business Wire - Fri Jun 27, 4:20PM CDT
Federico Pignatelli, former CEO and current director and stockholder of Biolase, Inc. (Nasdaq:BIOL), has initiated a process pursuant to Section 220(b) and (d) of the Delaware General Corporation Law to obtain certain books and records from Biolase management relating to suspected wrongdoing, mismanagement and corporate governance failures by the company's board of directors.
BIOLASE Announces Annual Meeting Date and Record Date
Business Wire - Thu Jun 26, 10:50PM CDT
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading manufacturer and distributor of dental lasers, is pleased to announce that its 2014 Annual Meeting of Shareholders will be held on August 27, 2014, at 11:00 a.m. Pacific Time at the Company's corporate headquarters, located at 4 Cromwell, Irvine, California, 92618. The Board of Directors has established July 22, 2014 as the record date for determining the stockholders entitled to vote at the 2014 Annual Shareholders Meeting.
BIOLASE Announces Significant Leadership Changes
Marketwire - Wed Jun 18, 1:27AM CDT
BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, today announced a series of moves with the intention of strengthening the Company's leadership, worldwide competitiveness and the focus on its professional customers and their patients.
Why Biolase (BIOL) Stock Is Higher Today
at The Street - Tue Jun 17, 10:09AM CDT
Biolase (BIO) stock is higher today after CEO Federico Pignatelli resigned following a Delaware Supreme Court's ruling last week over false advertising.
Oracle Partners Decisively Wins Shareholder Litigation Against Biolase, Inc.
Business Wire - Fri Jun 13, 9:28AM CDT
--Paul Clark Confirmed as Biolase Independent Director
BIOLASE Responds to Fotona Press Release Regarding Orange County, CA False Advertising Lawsuit
Marketwire - Thu Jun 12, 12:14PM CDT
BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, including the Company's proprietary WaterLase(R), and a pioneer in laser surgery in other medical specialties, as well as a distributor of digital radiography, intra oral scanners, and chair-side milling machines and 3-D printers for dentistry, today announced that it responds to clarify that this legal action is solely related to a false advertising and defamation suit filed by BIOLASE with the United States District Court in Orange County, California and does not affect the German Patent Infringement Suit won by BIOLASE in May awarding cash damages and injunctive relief. In addition, while the Orange County Court granted Fotona's Motion to Dismiss, they also elected to grant BIOLASE a 14 day Leave to Amend the Dismissed Claims which BIOLASE intends to pursue.
Federal Judge Dismisses Biolase Lawsuit Against Fotona
PR Newswire - Wed Jun 11, 1:00PM CDT
The Fotona companies, (Fotona), announced today, that on June 2, 2014, the federal judge in Orange County, California has dismissed all claims of Biolase's (BIOL) lawsuit against Fotona d.d. and Fotona LLC. Among other things, Biolase had challenged Fotona's statements that its lasers were faster for hard tissue dental applications than Biolase's lasers. The Court concluded that Biolase has failed to state a claim for false advertising since Fotona's advertising statements are accurate restatements of conclusions in scientific journal articles. Fotona will continue to vigorously defend its products, and take action against false or misleading claims.
BIOLASE Launches State-of-the-Art E-Learning Platform for Dentistry
Marketwire - Thu Jun 05, 1:45AM CDT
BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, including the company's proprietary WaterLase(R), and a pioneer in laser surgery in other medical specialties, as well as a distributor of digital radiography devices, intra-oral scanners, and chairside milling machines and 3-D printers for dentistry, today announced the launch of its state-of-the-art e-learning platform: BIOLASE Campus (www.biolasecampus.com). The site will go live on Monday, June 9, 2014.
Oracle Partners Announces a Victory in Shareholder Litigation Against Biolase, Inc.
PR Newswire - Fri May 30, 8:00AM CDT
Oracle Partners, L.P. ("Oracle Partners"
, Biolase, Inc.'s ("Biolase" or the "Company" (Nasdaq: BIOL) largest shareholder, announced that it has won a significant victory in its shareholder litigation against Biolase. UPDATE: BIOLASE Featured in Dental Tribune Report on Italy's Rimini Dental Conference
Marketwire - Thu May 29, 1:18PM CDT
BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, including the Company's proprietary WaterLase(R), and a pioneer in laser surgery in other medical specialties, as well as a distributor of digital radiography, intra oral scanners, and chair-side milling machines and 3-D printers for dentistry, today announced that it had been featured in a report on Dental Tribune's website.
BIOLASE Featured in Dental Tribune Report on Italy's Rimini Dental Conference
Marketwire - Thu May 29, 9:58AM CDT
BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, including the Company's proprietary WaterLase(R), and a pioneer in laser surgery in other medical specialties, as well as a distributor of digital radiography, intra oral scanners, and chair-side milling machines and 3-D printers for dentistry, today announced that it had been featured in a report on Dental Tribune's website.
Company calls BIOLASE Website Representations False and Misleading
Marketwire - Mon Mar 24, 12:53PM CDT
Millennium Dental Technologies Inc. (MDT) -- the world leader in dentist satisfaction of its signature value propositions LANAP(R) and LAPIP(TM) protocols -- has issued comments regarding false and misleading representations made by Biolase Inc. regarding a former MDT management level employee. The company considers the statements made by Biolase regarding MDT former vice president of global sales and marketing, Brian Jaffe, to be false and misleading.
BIOLASE announces formation of four member board
M2 - Mon Mar 24, 5:15AM CDT
Biomedical company BIOLASE (NASDAQ:BIOL) disclosed on Friday that the Chancery Court of Delaware has announced a status quo order to establish a board of directors.
Concise Analysis of the International Dental Diagnostic and Surgical Equipment Market
M2 - Mon Mar 24, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q52vzz/global_dental) has announced the addition of the "Concise Analysis of the International Dental Diagnostic and Surgical Equipment Market" report to their offering. The adoption of 3D cone-beam dental imaging in general dentistry, coupled with innovative implant procedures, oral surgery, temporo-mandibular joint analysis, and periodontal and orthodontic procedures, is an emerging trend that is expected to positively impact the Global Dental Diagnostic and Surgical Equipment market. Such innovative procedures make it possible to look at a tooth from any direction or orientation and in 3D, which eliminates much of the guesswork commonly experienced with 2D radiographs. The technique allows views of critical anatomy such as bone structure and tooth orientation to be captured. It aids in the accurate planning of procedures such as implants and oral surgery for more predictable outcomes, in addition to reducing treatment time and radiation. According to the report, one of the main drivers of this market is the increasing elderly population and the associated dental problems such as root caries, periodontal disease, missing teeth, edentulism, poor quality of alveolar ridges, various types of oral cancers, and caries. An increase in the edentulous population is also increasing demand for dental imaging and surgeries. Further, the report states that the market is experiencing challenges such as a lack of awareness of the risk of oral cancer, especially in developing countries such as Singapore, China, Brazil, and India. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Scope of the Report 4. Market Research Methodology 5. Introduction 6. Market Landscape 7. Market Segmentation by Product 8. Geographical Segmentation 9. Key Leading Countries 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 18. Key Vendor Analysis 19. Other Reports in this Series Companies Mentioned: - 3M Healthcare Ltd. - A-dec Inc. - Aribex Inc. - BIOLASE Inc. - Carestream Health Inc. - Danaher Corp. - Dental Equipment LLC and GC Corp. - Planmeca Oy. - Sirona Dental Systems Inc. For more information visit http://www.researchandmarkets.com/research/q5...bal_dental
